NVO [NYSE]
Novo Nordisk A/S
Index- P/E41.07 EPS (ttm)3.39 Insider Own26.40% Shs Outstand2.26B Perf Week-1.43%
Market Cap241.89B Forward P/E35.47 EPS next Y3.92 Insider Trans0.00% Shs Float1.21B Perf Month4.13%
Income7.74B PEG21.06 EPS next Q0.86 Inst Own8.40% Short Float / Ratio0.14% / 1.17 Perf Quarter30.44%
Sales24.49B P/S9.88 EPS this Y15.20% Inst Trans-5.21% Short Interest1.65M Perf Half Y19.82%
Book/sh4.97 P/B27.98 EPS next Y20.20% ROA24.80% Target Price139.83 Perf Year45.70%
Cash/sh3.16 P/C44.07 EPS next 5Y1.95% ROE73.30% 52W Range94.75 - 144.78 Perf YTD2.75%
Dividend1.60 P/FCF48.25 EPS past 5Y6.70% ROI48.60% 52W High-3.95% Beta0.50
Dividend %1.15% Quick Ratio0.70 Sales past 5Y4.70% Gross Margin84.20% 52W Low46.77% ATR2.48
Employees52696 Current Ratio0.90 Sales Q/Q27.90% Oper. Margin42.70% RSI (14)60.64 Volatility2.00% 1.55%
OptionableYes Debt/Eq0.34 EPS Q/Q20.40% Profit Margin31.60% Rel Volume1.03 Prev Close138.09
ShortableYes LT Debt/Eq0.31 EarningsNov 02 BMO Payout319.40% Avg Volume1.40M Price139.06
Recom1.30 SMA201.19% SMA506.70% SMA20022.09% Volume1,444,243 Change0.70%
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Apr-25-22Upgrade Cowen Market Perform → Outperform $130
Apr-12-22Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22Upgrade Deutsche Bank Hold → Buy
Jan-25-22Downgrade Liberum Hold → Sell
Dec-20-21Downgrade JP Morgan Overweight → Neutral
Show Previous Ratings
Jan-30-23 04:58PM
03:27PM
12:53PM
12:42PM
10:11AM
08:05AM Loading…
08:05AM
05:11AM
Jan-27-23 09:36AM
08:23AM
Jan-26-23 06:18PM
10:20AM
09:53AM
07:53AM
06:53AM
Jan-25-23 09:00AM
02:56AM Loading…
02:56AM
Jan-24-23 12:27PM
Jan-23-23 05:45PM
06:42AM
Jan-20-23 12:45PM
08:30AM
08:05AM
Jan-17-23 05:50PM
07:33AM
Jan-16-23 11:40AM
09:25AM
08:01AM
07:28AM
Jan-13-23 04:03PM
11:39AM
09:30AM Loading…
09:30AM
07:18AM
06:00AM
Jan-12-23 05:22PM
04:01PM
09:56AM
Jan-11-23 07:14PM
02:09PM
Jan-10-23 03:19PM
12:43PM
08:29AM
Jan-09-23 05:50PM
04:08PM
01:35PM
10:37AM
10:16AM
Jan-07-23 07:00AM
07:00AM
Jan-06-23 11:50AM
09:40AM
09:34AM
04:35AM
Jan-05-23 01:48PM
12:00PM
10:00AM
08:28AM
Jan-04-23 12:45PM
12:00PM
08:30AM
05:20AM
Jan-03-23 06:32AM
Dec-31-22 05:52PM
Dec-28-22 12:00AM
Dec-24-22 11:00AM
Dec-23-22 09:18AM
Dec-22-22 02:31PM
08:13AM
Dec-21-22 03:55PM
Dec-19-22 12:55PM
11:15AM
06:39AM
Dec-15-22 05:00AM
05:00AM
Dec-14-22 12:30PM
08:34AM
08:30AM
Dec-13-22 04:14PM
11:39AM
07:43AM
Dec-12-22 10:26AM
Dec-09-22 05:42PM
04:10PM
Dec-08-22 01:48PM
Dec-05-22 08:04AM
07:19AM
Dec-04-22 06:00AM
Dec-02-22 12:43PM
Dec-01-22 04:14PM
Nov-30-22 01:05PM
11:30AM
Nov-29-22 11:25AM
Nov-27-22 05:27PM
Nov-24-22 10:51AM
08:37AM
Nov-23-22 09:36AM
Nov-22-22 10:07AM
09:48AM
01:48AM
12:58AM
12:31AM
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.